Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BIOA
BIOAGE LABS INC.
NASDAQ
$9.59
▲ UP 0.95% (0.09)

KEY STATISTICS

Market Cap$361.06 M
52w High$25.95
52w Low$4.68
Dividend Yield—
Frequency—
P/E-4.03
Volume313.41K
Shares Out.37.65M

COMPANY

LEADERSHIP

Kristen Fortney
CHIEF EXECUTIVE
Kristen Fortney

COMPENSATION 2026

Salary$600,000
Stock Awards$0
Incentive Plan Pay$330,000
All Other Comp.$15,200
Total$2,886,590

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 26, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
61

PRICE TARGET

Target High$50.00
Target Low$21.00
Target Median$32.50
Target Consensus$34.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$1.53M
NOV
5
THU

PRICE

$9.59 ▲ UP 0.95% (+$0.09)
$9.45$9.60$9.759:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM9.59

About BioAge Labs Inc.

https://bioagelabs.com ↗

BioAge Labs is a clinical-stage biopharmaceutical company developing therapies for metabolic and neuroinflammatory diseases, including azelaprag for obesity and BGE-100 for neuroinflammation, leveraging aging insights and human datasets.

INDUSTRY

Biotechnology

A PRODUCT BIOAGE LABS INC. IS KNOWN FOR

BGE-102
BGE-102

BGE-102 is BioAge's oral, brain-penetrant NLRP3 inhibitor in Phase 1 for obesity, with plans for a mid-2026 proof-of-concept trial in diabetic macular edema.

COMPETITORS

COMPETITOR
LLY COMPARE
REGN COMPARE
SRRK COMPARE
VKTX COMPARE

Revenue by Products

IconPRODUCTQ1-2025Q2-2025Q3-2025
Operating Segments$1.45M $2.41M ▲$2.05M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
99
LISTED HERE
16
RANKED BY POSITION SIZE
VTI
0.00% · 1.1M
XSU.TO
0.01% · 901.3K
XPH
0.57% · 372.4K
FESM
0.03% · 197.4K
SCHA
0.01% · 151.0K
DFAS
0.01% · 108.8K
DWAS
0.23% · 100.3K
AVSC
0.02% · 59.6K
XRSU.L
0.01% · 31.3K
GSSC
0.02% · 22.3K
BBC
0.33% · 17.4K
RSSL
0.01% · 16.7K
PILL
0.39% · 9.4K
WCEO
0.50% · 6.4K
BIB
0.01% · 1.6K
USFMDN.MX
0.00% · 155

INSTITUTIONAL OWNERSHIP

SHARES OWNED
66.15%
HOLDERS
185
TOP 12 OF 185 · RANKED BY POSITION SIZE
Ah Capital Management, L.L.C.
3.2M sh · $56.55M
Cormorant Asset Management, LP
2.9M sh · $50.56M
Blackrock, Inc.
2.8M sh · $69.83M
Sofinnova Investments, Inc.
2.3M sh · $56.22M
Janus Henderson Group Plc
2.1M sh · $36.6M
Adar1 Capital Management, LLC
1.9M sh · $11.05M
Octagon Capital Advisors LP
1.7M sh · $42.84M
Ra Capital Management, L.P.
1.7M sh · $40.97M
Bioimpact Capital LLC
1.7M sh · $40.87M
Vanguard Group Inc
1.7M sh · $9.71M
Tang Capital Management LLC
1.6M sh · $9.41M
Balyasny Asset Management L.P.
1.3M sh · $23.22M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: PRINCIPAL ACCOUNTING OFFICER
Barton Shane
Sale · 9.3K shares
2026-06-29
★
OFFICER: PRINCIPAL ACCOUNTING OFFICER
Barton Shane
Purchase · 4.1K shares
2026-06-30
★
OFFICER: PRINCIPAL ACCOUNTING OFFICER
Barton Shane
Purchase · 4.0K shares
2026-06-30
★
OFFICER: PRINCIPAL ACCOUNTING OFFICER
Barton Shane
Purchase · 7.9K shares
2026-06-30

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
EQUAL WEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
BTIG BUY Needham BUY Citigroup BUY Jefferies BUY Morgan Stanley EQUAL WEIGHT

SECTORS PEERS

PEERPRICE
ALLO$1.97COMPARE
CABA$3.47COMPARE
EDIT$3.23COMPARE
AVIR$5.83COMPARE
CGC$0.97COMPARE
TKNO$6.92COMPARE
ACB$3.95COMPARE
LFCR$4.40COMPARE